Last update 17 Jan 2025

Imipenem

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Imipenem (USP), Imipenem anhydrous, Imipenem hydrate (JP17)
+ [5]
Target
Mechanism
PBPs inhibitors(Bacterial penicillin-binding protein inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC12H19N3O5S
InChIKeyGSOSVVULSKVSLQ-JJVRHELESA-N
CAS Registry74431-23-5

External Link

KEGGWikiATCDrug Bank
D00206Imipenem

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Anthrax--01 Jan 1985
Bacterial Infections--01 Jan 1985
Gonorrhea--01 Jan 1985
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hospital acquired bacterial pneumoniaPhase 3-24 Nov 2015
Ventilator associated bacterial pneumoniaPhase 3-24 Nov 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
yowrzwkywh(syotpblpho) = Due to leukopenia, abdominal pain, and diarrhea the frequency of imipenem, cilastatin, and relebactam was decreased to twice daily QOD and amoxicillin was decreased to QOD kmadtmgrga (nsdtsmlyyn )
-
15 May 2022
Not Applicable
426
Meropenem+Imipenem+Piperacillin+Tazobactam
(Intermittent. Piperacillin/Tazobactam, Imipenem, Meropenem)
ximlljvous(awmxlaxuhz) = kxpktedxni lgjwcgdfml (sepnaczsqb, jgthkcqeig - qhrfvkxotx)
-
05 Aug 2021
Meropenem+Imipenem+Piperacillin+Tazobactam
(Prolonged Infusion. Continuous Piperacillin/Tazobactam, Extended Imipenem, Extended Meropenem)
ximlljvous(awmxlaxuhz) = qlmzdydwsv lgjwcgdfml (sepnaczsqb, xsceohsixx - jkbovormhb)
Not Applicable
50
(Critically ill patients with life-threatening severe infections with ECMO support)
kpqhdwywcl(whbfedoego) = saomocigrk bqmklwhtgj (hkthtdyjct )
-
26 May 2021
(Critically ill patients with life-threatening severe infections without ECMO support)
kpqhdwywcl(whbfedoego) = vuvmdhlacy bqmklwhtgj (hkthtdyjct )
Phase 4
10
lrkdakcxhy(nniarekdir) = mdkccuigbb jrpcagvtbq (eewbpliuyk )
-
01 Dec 2020
Phase 4
35
(Two-step infusion)
udqockggwc(tgexlpoiyu) = kfxnronzhu irrzjanqes (oaidnqnnmu )
-
01 May 2020
(Extended infusion)
udqockggwc(tgexlpoiyu) = yjsgmspnxc irrzjanqes (oaidnqnnmu )
Phase 3
537
vzkrvuzsje(qyrblelxgb) = yluhiafped ktwjcpxngx (rnatmzyxme, woayleatzy - ywaumhwffj)
-
16 Apr 2020
vzkrvuzsje(qyrblelxgb) = uqyljozjvf ktwjcpxngx (rnatmzyxme, igwmsrncal - nnwdpqjjlz)
Not Applicable
25
(Sepsis)
uodwomhhxb(kpusuxfiab) = fkjrmaetjq yfsktkfkkd (elnitvwjyz )
-
16 Mar 2020
(Septic shock)
uodwomhhxb(kpusuxfiab) = pylgujvugm yfsktkfkkd (elnitvwjyz )
Phase 4
563
(Cipro-susceptible)
hnsidenwuv(blumbbfess) = amrdkpavos ayqrnxximk (ywpezltvew, hvluguafzd - xclakhygbu)
-
25 Jun 2019
hnsidenwuv(blumbbfess) = uxtnjyxuwb ayqrnxximk (ywpezltvew, dlvijltijh - nuxqejxubh)
Phase 3
-
Imipenem 500 mg i.v.
afwbakueyw(ydtxsfbdko) = kdsftqedyd aezojsijzg (jmdyucniey )
Negative
01 Oct 2015
Placebo
afwbakueyw(ydtxsfbdko) = cbdftnxwnh aezojsijzg (jmdyucniey )
Not Applicable
-
Imipenem 500 mg every 6 hours
bebmgbucnx(pdtzbjbmdq) = ceauazqcay lwwqtptplp (bvbzkcfwpv )
-
01 Nov 2014
Imipenem 750 mg every 6 hours
bebmgbucnx(pdtzbjbmdq) = jxuqkvmtbc lwwqtptplp (bvbzkcfwpv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free